Prenumeration
On February 13thth, Eevia Health Plc (publ) (“Eevia”) announced that the Company has initiated a EUR 2.6m sales transaction with Baccas Salus Oy, for equipment, products, and berry extract manufacturing IP. The transaction price exceeds the book value of the assets with EUR 1.5m, and the deal awaits approvals and payment from Baccas Salus Oy.
Read Analyst Group’s comment here
About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.
Read more about Analyst Group
This is a press release from Analyst Group regarding the publication of a comment on Eevia Health. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.